Nonagen Bioscience Corporation is a pioneer in the research and development of first-in-class diagnostics for the early detection and prediction of human cancers. By leveraging our deep understanding of biomarker discovery and validation to generate breakthrough diagnostics in oncology, we hope to improve clinical outcomes and cancer management. Paving the way toward our goal is our lead diagnostic: Oncuria®, a liquid biopsy for the noninvasive detection of bladder cancer. This cutting-edge urine-based test measures 10 biomarkers associated with bladder cancer. Oncuria is being developed to aid in the diagnosis of bladder cancer; monitor people with early-stage bladder cancer for recurrence; and predict which people are more likely to respond to the first-line treatment, intravesical bacillus Calmette-Guérin (BCG) therapy. The promise of Oncuria’s clinical utility is evident in the Breakthrough Device Designation it received from the US Food and Drug Administration (FDA) for predicting response to BCG. Learn more about the potential benefits of Oncuria and how it could help advance the diagnosis of bladder cancer at www.nonagenbioscience.com/products.